Effect of Yohimbine on Colon Transit - Full Text View

Effect of Yohimbine on Colon Transit

This study is currently recruiting participants.
Verified by Mayo Clinic, September 2005

Sponsors and Collaborators:	Mayo Clinic National Institutes of Health (NIH)
Information provided by:	Mayo Clinic
ClinicalTrials.gov Identifier:	NCT00217048

Purpose

This study is being done to learn if yohimbine, a naturally occurring drug, affects the speed at which food travels through the stomach, intestines and colon, and if yohimbine affects the amount of liquid you can drink in a short period of time. Understanding how yohimbine works on the gut may help develop new treatments for patients with constipation. Yohimbine has been approved by the Food and Drug Administration (FDA) for routine clinical use, however, its use as proposed in this study is considered investigational.

Condition	Intervention	Phase
Healthy Volunteers	Drug: Yohimbine, oral	Phase I Phase II

ChemIDplus related topics:

Yohimbine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Official Title:	Effect of Oral Yohimbine on Colonic Transit: Randomized, Placebo-Controlled Trial

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:

Colonic transit

Secondary Outcome Measures:

Small bowel transit time
Gastric emptying time
Maximum tolerated volume ingested during satiation testing
Average stools per day
Stool consistency

Estimated Enrollment:	30
Study Start Date:	June 2005
Estimated Study Completion Date:	October 2005

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Healthy male or non-pregnant, non-breastfeeding female volunteers, -18-65 years old;
Able to provide written informed consent before participating in the study;
Able to communicate adequately with the investigator and to comply with the requirements for the entire study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00217048

Locations


United States, Minnesota
	Mayo Clinic	Recruiting
	Rochester, Minnesota, United States, 55905
	Contact: Barb Seide 507-255-6802
	Principal Investigator: Adil E Bharucha, MBBS, MD

Sponsors and Collaborators

Mayo Clinic

National Institutes of Health (NIH)

Investigators


Principal Investigator:	Adil E Bharucha, MBBS, M.D.	Mayo Clinic

More Information

Study ID Numbers:	275-05
First Received:	September 16, 2005
Last Updated:	September 16, 2005
ClinicalTrials.gov Identifier:	NCT00217048
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Yohimbine

Healthy

Additional relevant MeSH terms:

Neurotransmitter Agents

Mydriatics

Molecular Mechanisms of Pharmacological Action

Adrenergic Agents

Autonomic Agents

Physiological Effects of Drugs

Adrenergic Antagonists

Peripheral Nervous System Agents

Adrenergic alpha-Antagonists

Pharmacologic Actions

ClinicalTrials.gov processed this record on September 05, 2008